Thyroid cancer is the most common endocrine neoplasm and the incidence continues to rise worldwide. For many patients, standard therapy is effective for achieving long-term survival. Patients who develop aggressive or recurrent diseases represent a considerable therapeutic challenge, thus the search for novel treatment strategies for these difficult cases remains a key component of ITOG’s mission.
ITOG has partnered with pharmaceutical companies and other cancer groups in a concentrated effort to make headway in finding a path forward for these aggressive tumor types. Below, please find a list of ITOG’s active and upcoming clinical trials.